{"id":23767,"date":"2022-12-07T16:54:00","date_gmt":"2022-12-07T08:54:00","guid":{"rendered":"https:\/\/flcube.com\/?p=23767"},"modified":"2025-01-29T17:00:00","modified_gmt":"2025-01-29T09:00:00","slug":"maxhealth-biotechnology-completes-series-b-financing-round","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=23767","title":{"rendered":"MaxHealth Biotechnology Completes Series B+ Financing Round"},"content":{"rendered":"\n

Chengdu-based vaccine developer MaxHealth Biotechnology LLC announced the completion of a Series B+ financing round at RMB 200 million (USD 28.64 million), led by GF Qianhe Investment. Other investors included existing investors China Life Private Equity Investment, and Wuxi Xinshang Investment, alongside new investors LongRiver Investments, Sealand Innovation, and Guangdong Mintou Private Equity Fund. Proceeds will go towards clinical studies for multiple vaccine pipelines, human vaccine manufacturing base construction, and talent team expansion and improvement. The company has raised a total of RMB 800 million (USD 114.6 million) via two financing rounds this year.<\/p>\n\n\n\n

Company Background and Technology Platforms<\/strong>
Founded in 2016, MaxHealth Bio boasts a world-leading new adjuvant platform, recombinant protein expression platform, and mRNA platform with a product pipeline consisting of preventative vaccines and therapeutic vaccines targeting hepatitis B virus (HBV), allergic diseases, and tumors. The company, with research and development centers in Chengdu, Shanghai, and Hangzhou, has two products in clinical stages.-Fineline Info & Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

Chengdu-based vaccine developer MaxHealth Biotechnology LLC announced the completion of a Series B+ financing round…<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":false,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[30,20,3374,63],"class_list":["post-23767","post","type-post","status-publish","format-standard","hentry","category-company","category-deals","tag-biotech","tag-finance","tag-maxhealth-biotechnology","tag-mrna"],"yoast_head":"\nMaxHealth Biotechnology Completes Series B+ Financing Round - Insight, China's Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Chengdu-based vaccine developer MaxHealth Biotechnology LLC announced the completion of a Series B+ financing round at RMB 200 million (USD 28.64 million), led by GF Qianhe Investment. Other investors included existing investors China Life Private Equity Investment, and Wuxi Xinshang Investment, alongside new investors LongRiver Investments, Sealand Innovation, and Guangdong Mintou Private Equity Fund. Proceeds will go towards clinical studies for multiple vaccine pipelines, human vaccine manufacturing base construction, and talent team expansion and improvement. The company has raised a total of RMB 800 million (USD 114.6 million) via two financing rounds this year.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=23767\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"MaxHealth Biotechnology Completes Series B+ Financing Round\" \/>\n<meta property=\"og:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=23767\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China's Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2022-12-07T08:54:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-01-29T09:00:00+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=23767#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=23767\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"MaxHealth Biotechnology Completes Series B+ Financing Round\",\"datePublished\":\"2022-12-07T08:54:00+00:00\",\"dateModified\":\"2025-01-29T09:00:00+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=23767\"},\"wordCount\":161,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Biotech\",\"Finance\",\"MaxHealth Biotechnology\",\"mRNA\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=23767#respond\"]}],\"copyrightYear\":\"2022\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=23767\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=23767\",\"name\":\"MaxHealth Biotechnology Completes Series B+ Financing Round - Insight, China's Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2022-12-07T08:54:00+00:00\",\"dateModified\":\"2025-01-29T09:00:00+00:00\",\"description\":\"Chengdu-based vaccine developer MaxHealth Biotechnology LLC announced the completion of a Series B+ financing round at RMB 200 million (USD 28.64 million), led by GF Qianhe Investment. Other investors included existing investors China Life Private Equity Investment, and Wuxi Xinshang Investment, alongside new investors LongRiver Investments, Sealand Innovation, and Guangdong Mintou Private Equity Fund. Proceeds will go towards clinical studies for multiple vaccine pipelines, human vaccine manufacturing base construction, and talent team expansion and improvement. The company has raised a total of RMB 800 million (USD 114.6 million) via two financing rounds this year.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=23767#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=23767\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=23767#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"MaxHealth Biotechnology Completes Series B+ Financing Round\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"MaxHealth Biotechnology Completes Series B+ Financing Round - Insight, China's Pharmaceutical Industry","description":"Chengdu-based vaccine developer MaxHealth Biotechnology LLC announced the completion of a Series B+ financing round at RMB 200 million (USD 28.64 million), led by GF Qianhe Investment. Other investors included existing investors China Life Private Equity Investment, and Wuxi Xinshang Investment, alongside new investors LongRiver Investments, Sealand Innovation, and Guangdong Mintou Private Equity Fund. Proceeds will go towards clinical studies for multiple vaccine pipelines, human vaccine manufacturing base construction, and talent team expansion and improvement. The company has raised a total of RMB 800 million (USD 114.6 million) via two financing rounds this year.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=23767","og_locale":"en_US","og_type":"article","og_title":"MaxHealth Biotechnology Completes Series B+ Financing Round","og_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","og_url":"https:\/\/flcube.com\/?p=23767","og_site_name":"Insight, China's Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2022-12-07T08:54:00+00:00","article_modified_time":"2025-01-29T09:00:00+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=23767#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=23767"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"MaxHealth Biotechnology Completes Series B+ Financing Round","datePublished":"2022-12-07T08:54:00+00:00","dateModified":"2025-01-29T09:00:00+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=23767"},"wordCount":161,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Biotech","Finance","MaxHealth Biotechnology","mRNA"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=23767#respond"]}],"copyrightYear":"2022","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=23767","url":"https:\/\/flcube.com\/?p=23767","name":"MaxHealth Biotechnology Completes Series B+ Financing Round - Insight, China's Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2022-12-07T08:54:00+00:00","dateModified":"2025-01-29T09:00:00+00:00","description":"Chengdu-based vaccine developer MaxHealth Biotechnology LLC announced the completion of a Series B+ financing round at RMB 200 million (USD 28.64 million), led by GF Qianhe Investment. Other investors included existing investors China Life Private Equity Investment, and Wuxi Xinshang Investment, alongside new investors LongRiver Investments, Sealand Innovation, and Guangdong Mintou Private Equity Fund. Proceeds will go towards clinical studies for multiple vaccine pipelines, human vaccine manufacturing base construction, and talent team expansion and improvement. The company has raised a total of RMB 800 million (USD 114.6 million) via two financing rounds this year.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=23767#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=23767"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=23767#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"MaxHealth Biotechnology Completes Series B+ Financing Round"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/23767","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=23767"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/23767\/revisions"}],"predecessor-version":[{"id":23769,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/23767\/revisions\/23769"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=23767"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=23767"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=23767"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}